Beigene Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BEIGENE, and what generic alternatives to BEIGENE drugs are available?
BEIGENE has one approved drug.
There are eleven US patents protecting BEIGENE drugs.
There are sixty-four patent family members on BEIGENE drugs in twenty-nine countries and eleven supplementary protection certificates in eleven countries.
Drugs and US Patents for Beigene
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Beigene | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | RX | Yes | Yes | 11,911,386 | ⤷ Sign Up | ⤷ Sign Up | ||||
Beigene | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | RX | Yes | Yes | 11,851,437 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Beigene | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
Beigene | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
Beigene | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | RX | Yes | Yes | 9,447,106 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Beigene | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | RX | Yes | Yes | 10,570,139 | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Beigene Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Eurasian Patent Organization | 201990519 | ⤷ Sign Up |
Poland | 2989106 | ⤷ Sign Up |
South Africa | 201900919 | ⤷ Sign Up |
New Zealand | 711540 | ⤷ Sign Up |
Japan | 2022071072 | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 2023240180 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Beigene Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2989106 | PA2022504 | Lithuania | ⤷ Sign Up | PRODUCT NAME: ZANUBRUTINIBAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA ; REGISTRATION NO/DATE: EU/1/21/1576 20211121 |
2989106 | 4/2022 | Austria | ⤷ Sign Up | PRODUCT NAME: ZANUBRUTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/21/1576 (MITTEILUNG) 20211123 |
2989106 | C02989106/01 | Switzerland | ⤷ Sign Up | FORMER OWNER: BEIGENE, LTD., KY |
2989106 | 122022000013 | Germany | ⤷ Sign Up | PRODUCT NAME: ZANUBRUTINIB ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/21/1576 20211122 |
2989106 | 2022C/508 | Belgium | ⤷ Sign Up | DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT |
2989106 | 301161 | Netherlands | ⤷ Sign Up | DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.